Coherus Oncology
CHRS
38 hedge funds and large institutions have $158M invested in Coherus Oncology in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$43.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$21.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.7M |
| 4 |
VM
VHCP Management
New York
|
+$12.3M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
+$11M |
Top Sellers
CHRS Hedge Fund Activity: Q4 2014 in Review
38 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2014, worth a combined $158M.
Buyers outnumbered sellers: 38 funds opened new CHRS positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kohlberg Kravis Roberts & Co, opening a new position worth an estimated $43.1M.
- 38 institutional investors held Coherus Oncology (CHRS) as of Q4 2014, up from 0 in Q3 2014.
- Funds reported $158M of Coherus Oncology stock for Q4 2014.
- 38 funds opened new Coherus Oncology positions in Q4 2014 and 0 closed out, a net change of +38 holders.
- The largest Coherus Oncology buyer in Q4 2014 was Kohlberg Kravis Roberts & Co, an estimated $43.1M added.
Based on aggregated 13F filings for Q4 2014.